-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Candel Therapeutics, Lowers Price Target to $13

Benzinga·11/13/2026 13:40:05
Canaccord Genuity analyst John Newman maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $25 to $13.